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While there has been a progress in understanding P. falciparum genomics, and exciting 
discoveries of promising leads in the antimalarial pipeline, the efficacies of existing 
artemisinin combination therapies are threatened by incorrect dosing and non-compliance 
with duration of dosing regimen, which might hasten the emergence of resistant parasites. 
Understanding of the effects of drug interactions on combination therapy with existing 
antimalarial agents may provide useful information such as their mechanism of action, 
and influence the development of new drug combination. A traditional way of evaluating 
antimalarial drug efficacy and combined drug interactions has been relying on in vitro 
drug sensitivity assays using cultured cells. This method measures the rate of suppression 
or inhibition of parasite growth during 48 – 72 hours in comparison to untreated controls. 
However, extrapolating in vitro results from cultured parasites to humans remains 
challenging as cytocidal activity of antimalarials (reduction in absolute parasite numbers) 
 




in patients is measured at a high asynchronous parasitemia at close to 1 trillion (per 
adult).  
In this thesis, we adapted a transgenic luciferase reporter, P. berghei ANKA to 
study cytocidal activity of tafenoquine and pyronaridine in mice for combinations of 
three current antimalarials, artesunate, amodiaquine, and azithromycin at clinically 
relevant dosage. We initiated each drug treatment at a high parasitemia (~10%) and 
followed for 30 days. Three metrics of measures we used in characterizing 
pharmacodynamic properties are 30-day survival, parasite log reduction over 48 hours, 
and recrudescent parasitemia (i.e., return to initial parasitemia). We adapted the parasite 
reduction ratio (PRR), or fractional log reduction in parasitemia as the PRR can be 
analogous to the killing rate, thus serving as a measure to compare the different intrinsic 
pharmacodynamic between the drugs in question. Pyronaridine when compared to 
tafenoquine at the same dose exhibited more potent cytocidal activity with approximately 
1,000-fold more reduction in the number of parasite over the single 24-hour parasitic life 
cycle. Tafenoquine synergized with artesunate. In contrast, additive interactions were 
evident for pyronaridine in combination with artesunate. In addition, while pyronaridine 
synergized amodiaquine, differential interactions were shown with azithromycin, 
suggesting that synergy may only be achieved at certain dose ratios.  
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An introduction to Plasmodium spp. and 
antimalarial chemotherapy  
 
1.1 Malaria  
Malaria, a mosquito-borne, acute febrile illness caused by a protozoan parasites of 
the genus Plasmodium, remains one of the life-threatening infectious diseases 
with 216 million cases and 445,000 deaths(1). In humans, five different 
Plasmodium species, namely P. falciparum, P. vivax, P. ovale, P. malariae, and 
P. knowlesi can cause malaria through the bites of infected female mosquitoes of 
the genus Anopheles. While other Plasmodium species remain important causes of 
significant disease, including severe illness, P. falciparum and P. vivax pose the 
greatest public health challenge globally. Infection with P. falciparum is most
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prevalent on the African continent where more than two thirds (70%) of all fatal malaria 
cases occur in children under age 5. P. vivax has a wider geographical distribution, 
covering most countries outside of sub-Saharan Africa owing to its ability to develop in 
the Anopheles mosquito at lower temperatures (below 20

C) and survive at higher 
altitudes. In case of P. vivax and P. ovale malaria, parasites have an advantage of having 
a dormant liver-resident hypnozoite stage, producing no clinical manifestation, but 
causing recrudescence or relapse months or years after initial antimalarial treatment (2, 3)
 
 
Figure 1.1 Plasmodium Life Cycle. Stages in both human host and mosquito vector. Reprinted by 
permission from American Society for Clinical Investigation: the Journal of Clinical Investigation. 
“Antimalarial drug resistance” by Nicholas J. White, copyright (2004). 





Plasmodium spp. have a complex life cycle. A complete cycle involves both 
humans and female Anopheles mosquitoes and distinct forms at specific life stages to 
invade different cell types (Fig. 1.1). Human-to-human transmission of malaria occurs 
through an infected female Anopheles, serving as a vector. In vertebrate hosts, the 
parasites are injected as highly motile “sporozoites” into the host dermis during a blood 
feed. Only a proportion exits the dermis, entering the bloodstream and quickly 
transported to the liver, where the sporozoites invade hepatocytes. The remaining 
parasites in the skin are cleared by a host immune response. Upon successful infection of 
hepatocytes, the sporozoites develop to an exo-erythrocytic form in the liver, releasing up 
to 40,000 merozoites per hepatocyte into the bloodstream in packets of merosomes. Free 
merozoites can infect erythrocytes at any age within a very short time, and the parasites 
develop to asexual, erythrocytic (ring) stage. While little is understood about the 
molecular details of interactions with erythrocytes, merozoites surface protein 1 (MSP1), 
the major glycophosphatidylinositol (GPI)-associated protein on the merozoites surface, 
is largely involved in merozoites invasion of erythrocytes (4). The initial interactions of 
merozoites are irreversible, resulting in deformation of the red cells. Once erythrocytic 
infection is established, the parasites take 48-hour life cycle to asexually multiply 
approximately tenfold in the red cells (erythrocytic schizogony) and mature into 
schizonts which then eventually rupture, releasing a brood of merozoites to invade new 
host cells. The blood stage parasites are responsible for the clinical symptoms of malaria. 
In fact, malaria pathology in human hosts is caused by Plasmodium-infected erythrocytes 
binding to vascular endothelial cells in various organs, such as the heart, brain, kidney, 





lungs and liver(5). The P. falciparum erythrocyte membrane protein 1 (PfEMP1) family, 
extremely diversified proteins expressed on the surface of the P. falciparum-infected red 
cells, plays the central role in host immunity and pathogenesis as their display exposes 
them to host antibodies. PfEMP1 proteins, however, are able to evade immune 
destruction, thus escaping splenic clearance, and maintain a chronic infection via 
antigenic variation. In addition to PfEPMP1 family, a wide array of extrinsic proteins is 
exported to the infected erythrocytes. This process of renovation of erythrocyte structure 
allows parasites to scavenge nutrients and hide from host immune responses(6). The main 
source of food for Plasmodium spp. is the host cell hemoglobin. The parasites digest 
hemoglobin and crystalize heme, a potentially toxic byproduct of the process, producing 
hemozoin (or malaria pigment). At some points in a schizogony cycle, merozoites in an 
infected red cell develop into either asexual schizonts or sexual male or female 
gametocytes. While molecular details of this transition remain inconclusive, it is evident 
that parasites can regulate gametocyte production by sensing their environmental stimuli 
e.g., high parasitemia and drug exposure (7)). 
The sexual stage of Plasmodium begins when gametocytes are ingested by a 
female Anopheles mosquito during a blood feed. A zygote is formed after the fusion of 
gametes in the mosquito’s stomach. The zygote develops into motile and elongated 
ookinetes which can penetrate into the mosquito’s midgut and develop into the next 
stage, oocysts. The oocysts undergo multiplication, result in explosive release of 
sporozoites. The free sporozoites travel to the mosquito’s salivary glands, and are 
injected with the mosquito’s saliva during a blood meal.  





Clinical symptoms of human malaria infection in a non-immune individual 
involve fever, chills and non-specific headache and muscle pains approximately 14 days 
after the infective mosquito bite. When P. falciparum malaria is untreated or partially 
treated, initial infection progresses to severe malaria, which may lead to anemia, multi-
organ failure and death(8). Asymptomatic infections may occur in older children and 
adults with naturally acquired immunity in stably endemic areas in which exposure to 
infected mosquitoes is high, and thus transmission level is more consistent year-to-year. 
In the case of P. vivax and P. ovale malaria, a prolonged treatment is required as 
reactivation of the dormant liver-resident hypnozoite may occur at intervals. Historically, 
due to a very low incidence of deaths reported from P. vivax malaria, it has been regarded 
as a relatively benign parasite. However, this perception is increasingly challenged by 
recent studies reporting a substantial amount of morbidity, severe disease, and mortality 
due to P. vivax, particularly among infants(9). Generally, malaria case fatality is much 
higher in individuals exposed to multiple and concurrent health risks such as HIV 
infection. Malaria infection is also associated with an increased prevalence of invasive 
bacterial disease and inflammatory bowel disease (IBD)(10, 11).    
Accurate and prompt diagnosis of malaria remains a critical factor for effective 
disease management and surveillance. Due to variable and non-specific clinical 
symptoms of malaria, parasite-based diagnostic testing is recommended prior to initiating 
antimalarial treatment on patients with suspected malaria. Such practice helps prevent the 
emergence and spread of antimalarial drug resistance by limiting antimalarials use to test-
positive cases. Microscopy of blood films with Giemsa stain and malaria rapid diagnostic 





test (RDT) are the two primary options for diagnosing malaria. Three most vital pieces 
information that microscopy diagnosis can provide are the presence of parasites in 
patient’s blood, identification of Plasmodium species and the parasitemia. RDT dipstick 
is another rapid way of detecting specific malaria antigens in a patient’s blood specimen. 
The test is able to differentiate between antigen specific for P. falciparum and one found 
in all 4 human malaria species. RDTs, however, may fail to detect infections with low 
parasitemia, and P. ovale and P. malariae malaria. Therefore, microscopy diagnosis of 
malaria is required to speciate or quantify the parasite load. In addition to microscopy and 
malaria RDT, serology and molecular diagnosis are available. While these techniques 
may be more sensitive than microscopy and RDT, serology measures previous exposure, 
thus not representing the current infection, and molecular diagnosis using polymerase 
chain reaction (PCR) is not readily available in many resource-limited, malaria endemic 
countries.  
Historically, malaria prevention tools, including indoor residual spraying (IRS), 
insecticide-treated bed nets (ITN), and environmental strategies such as reduction or 
permanent destruction of mosquito larval habitats have contributed greatly to malaria 
control and elimination efforts. IRS prevents human-to-human transmission by targeting 
endophilic mosquito’s resting behaviors. A few examples of key malaria vectors in sub-
Saharan Africa that IRS is most successful with killing are Anopheles gambiae s.s. and 
Anopheles funestus. ITN provides a protective barrier around people sleeping under them 
by killing and repelling mosquitoes, as well as other insects. Pyrethroids are the only 
chemicals approved for use on ITNs.  In addition to IRS and ITN, the development of 





vaccines against malaria has been a major focus of the malaria research since the early 
20
th
 century. Many of these studies can be broadly categorized into three approaches: pre-
erythrocytic stages which include sporozoites and hepatocyte invasion to stop 
establishment of blood stage infection, asexual stages to  control clinical symptoms, and 
sexual stages to interrupt the transmission cycle between human and mosquito vectors. 
The majority of vaccine attempts have been focused on the most significant strain, P. 
falciparum using circumsporozoite protein (CSP), a highly repetitive region on the 
sporozoites. However, the complexity of Plasmodium complicates the development of 
preventive malaria vaccine. Highly polymorphic nature of Plasmodium antigens and poor 
immunogenicity are few examples. Ideally, a safe and effective malaria vaccine induce 
sterile protection with as few doses as possible, and an ideal strategy may be targeting 
multiple lifecycle stages. With the current inconclusive understanding of the human 
immune system and its interactions with malaria parasites, malaria control today heavily 
relies on safe and effective antimalarial drugs for both treatment of established infection 
and prevention of malaria.
 
1.2 Antimalarial chemotherapy 
The primary goal of antimalarial drug treatment in malaria is to kill asexual, 
intraerythrocytic-stage parasites (the stage that causes disease), thereby reducing parasite 
number and leading to their immediate removal from the peripheral circulation(12). Most 
antimalarial drugs target these stages, and are called blood schizonticides. Today, the use 
of single drugs is not recommended in the clinic for various reasons, including the 





emergence of resistant parasites. Current international guidelines recommend the use of 
artemisinin-based combination therapy (ACT) as a first-line treatment on a three-day 
course schedule, as artemisinin derivatives, particularly, artesunate, can rapidly reduce 
the parasitic load by at least 10,000-fold within 48 hours of the parasitic life cycle, 
resulting in greater than 95% clearance of initial infection. Based on the mode of action, 
common partner drugs for ACTs are classified into three groups: antifolates, quinolines 
(4-aminoquinolines, quinoline alcohols and 8-aminoquinolines), and antibiotics.  
 
Artemisinin derivatives 
Naturally occurring artemisinin is not used clinically; rather it has been replaced 
by its semisynthetic derivatives artesunate (and artemether) or by the metabolite 
of the semisynthetic derivatives, dihydroartemisinin (DHA)(13). Artemisinin 
derivatives and DHA are activated by iron and or heme to cause radical damage to 
surrounding proteins, resulting in reduction of the total parasite burden more 
rapidly than other antimalarials(14). While fast-acting schizonticidal activity 
remains the greatest advantage, both artemisinin derivatives and DHA have a 
short half-life of less than a few hours, requiring a partner drug with a longer half-
life to clear residual parasites(15, 16).  
 
Antifolates 
Antifolate antimalarial drugs (e.g., pyrimethamine, sulfonamide) interfere with 
folate metabolism, a pathway essential to malaria parasite survival, thereby 





interrupting the synthesis of DNA(17). Similar to other antimalarial drug classes, 
the antifolates appear to affect only the actively dividing schizonts rather than the 
young parasites in their early stages during the first 24 hours(18). This class of 
drugs include effective causal prophylactic and therapeutic agents against P. 
falciparum, some of which act synergistically when used in combination. 
Unfortunately, due to mutations in the genes in two key target enzymes i.e., 
dihydrofolate reductase (DHFR), dihydropteroate synthase (DHPS), resistance to 
the antifolates has arisen relatively rapidly and is now common worldwide(19).  
 
Quinolines 
The quinoline-containing drug class includes some of the most commonly used 
antimalarials, such as aryl-amino alcohols quinine and mefloquine. Quinine, a 
component of the bark of the cinchona tree offered the most effective treatment of 
malaria as early as the 1600s with cure rates of greater than 98%(20). Quinine 
continues to play a major role today in the management of malaria in pregnancy, 
although its use for the treatment of uncomplicated malaria has been replaced by 
newer and better tolerated therapies such as ACT. The primary mode of action of 
quinine involves interfering with heme detoxification process of intra-
erythrocytic-stage parasites. Quinine and structurally related compound, 
mefloquine share similar modes of antimalarial action against falciparum and 
vivax malaria as noted by Schmidt in 1978(21). One example is quinine- and 
mefloquine-induced morphological changes in the early ring stages. While 





resistance to quinine and mefloquine, and cross resistance between these two 
compounds limited the clinical usefulness of these compounds, particularly in 
Southeast Asia, mefloquine remains a priority antimalarial chemoprophylaxis for 
travelers to high risk malarial endemic areas(22, 23).  
The rest of quinoline-related compounds can be broadly categorized into 
three classes: 4-aminoquinoline, quinoline alcohols and 8-aminoquinoline. The 
primary mode of action for the non 8-aminoquinoines is much like that of quinine, 
involving interference with intraerythrocytic parasite, particularly its heme 
detoxification by inhibiting the dimerization or crystallization process that 
produces hemozoin. A number of key 4-aminoquinoline compounds include 
chloroquine, pyronaridine, and amodiaquine. For the purpose of the present study, 
the following discussion is focused on pyronaridine, amodiaquine, and 
tafenoquine.  
4-aminoquinolines 
 Pyronaridine was first synthesized in 1970 in China, and 
developed for the treatment of acute uncomplicated P. falciparum 
and blood stage P. vivax malaria. In previous in vitro and ex vivo 
studies, the drug demonstrated high efficacy against both 
chloroquine and amodiaquine-resistant strains of P. falciparum(24, 
25). Pyronaridine is a promising therapeutic partner to use in 
artemisinin combination therapy, as it appears to delay the 
development of resistance and show synergistic interactions with 





artemisinin derivatives, such as dihydroartemisinin (DHA) and 
artesunate, against strains resistant to the individual components or 
both in in vivo animal studies(26, 27). The drug is administered as 
pyronaridine tetraphosphate (56.89% free base), and as with other 
4-aminoquinolines, pyronaridine works by interfering with 
parasite’s food vacuole, and inhibits the heme crystallization by 
blood stage parasite(28, 29).  
 Amodiaquine is structurally related to chloroquine and 
pyronaridine, and has a potent blood schizonticidal activity against 
chloroquine-resistant strains of falciparum malaria in humans (30). 
While it was widely used in the past for both treatment and 
prevention, the clinical use of amodiaquine, specifically for 
prophylactic use has been severely limited today because of 
associations with hepatotoxicity and agranulocytosis (31). When 
used as treatment, however, amodiaquine has a number of 
advantages, including affordability, efficacy against many (not all) 
chloroquine-resistant strains of P. falciparum, and relatively fair 
tolerability when used as treatment(32). In a randomized trial led 
by Muller et al in 1996, amodiaquine demonstrated its superior 
efficacy over chloroquine in the treatment of uncomplicated 
malaria in Gambian children (33). While the drug shares a similar 
mode of action with other 4-aminoquinolines, and cross-resistance 





is possible, its unique ability to remain at high concentration in 
parasitized erythrocytes in falciparum malaria explains its 
effectiveness in previous in vitro, and in vivo studies in areas with 
a high level of chloroquine resistance (34-36).  
8-aminoquinolines 
While mechanisms of action have not been clearly defined, the 8-
aminoquinolines e.g., pamaquine, primaquine and tafenoquine show a 
number of attractive antimalarial properties, including causal prophylactic 
activity as well as acting against the transmission-stage gametocytes. 
Particularly, primaquine has a marked gametocytocidal activity against P. 
falciparum, and remains the drug of choice for treatment of vivax (and 
ovale) malaria, as radical cure (eradication of the dormant liver 
hypnozoites) can only be achieved by the drug. However, a short 
biological half-life (4-6 hours), lengthy treatment course of 14 days, and 
severe side effect i.e., hemolysis to people who are deficient in glucose-6-
phosphate dehydrogenase (G6PD) limit its use. Tafenoquine, a new 
synthetic primaquine analog with a longer elimination half-life (14-28 
days) and fewer adverse effects, has demonstrated greater activity than 
primaquine against blood- and liver-stage parasites in vitro, including 
multi-drug resistant P. falciparum strains, and in vivo animal studies(37-
39). However, like primaquine, tafenoquine can cause G6PD deficient 
patients to experience hemolysis. Tafenoquine is formulated as salt, and 





dosed as tafenoquine succinate salt whose free base is 80% of the total salt 
(40). Its mode of action against erythrocytic parasites is similar to that of 
4-aminoquinolines, with an additional mechanism involving interference 
with mitochondrial function of parasites in the liver- and gametocyte 
stage(41, 42). While currently not approved for use, tafenoquine is in stage 
3 of clinical trials, and presents a potential alternative to primaquine for 
both prevention and treatment of malaria. In vivo studies of drug 




Atovaquone is a hydroxynaphthoquinone, used for both the treatment and 
prevention of malaria in fixed combination with proguanil (Malarone®). The 
combination is highly synergistic in vitro and effective against strains that are 
resistant to a variety of other antimalarial drugs(43). Clinical studies demonstrated 
enhanced efficacy of atovaquone in combination with proguanil with a significant 
reduction in the rate at which parasites resistant to both drugs develop(44). The 
mode of action and synergy with proguanil are not fully understood while the 
combination is believed to act on the parasite in the early liver stages of P. 
falciparum, and the erythrocytic stages of P. vivax, P. ovale, and P. malariae, and  
atovaquone acts primarily on mitochondrial functions, inhibiting the electron 
transport system at the level of cytochrome bc1 complex(45, 46). Malaria 





parasites require a coupling of pyrimidine biosynthesis and electron transport, and 
the novel mechanism of action of atovaquone, in fact, takes an advantage of the 
fact that Plasmodium spp. are dependent on de novo pyrimidine biosynthesis 
while mammalian cells can simply salvage and recycle pyrimidines(47). The 
inability of parasites to retrieve premade pyrimidines results in atovaquone 
blocking nucleic acid synthesis and thus replication.  
 
Antibiotics  
The greatest advantage of using antibiotics in the treatment of malaria comes from 
the fact that many antibiotics have mechanisms of action likely to be different 
from those of most traditional antimalarials. This could contribute to combination 
therapies as the probability of developing drug resistance is greatly reduced. 
Antibiotics inhibit the translation machinery of the apicoplast which is essential 
for the synthesis of fatty acids, isoprenoids, and heme, thereby arresting the 
parasites in the schizont stage and preventing further formation of merozoites in 
the following replication cycle. Interestingly, this unique activity of antibiotics 
leads to a slow killing of the parasite, affecting the next replication cycle rather 
than the time point when the antibiotic is first introduced(48-50). This is termed 
“delayed death effect,” and is observed in most antibiotics active against malaria, 
including clindamycin and azithromycin(51, 52). Antibiotics are used in 
combination with traditional antimalarial drugs, particularly against multidrug-
resistant P. falciparum. A number of successful cases in the past include 





combination of tetracyclines with quinine and mefloquine to treat multidrug-
resistant P. falciparum in Thailand, and the artesunate-tetracycline combination in 
Brazil(53, 54). However, the use of tetracyclines is limited by its poor safety 
profiles in young children and pregnant women. Clindamycin is commonly 
combined with either chloroquine or quinine to treat children with uncomplicated 
falciparum malaria(55). Erythromycin has demonstrated its potent antimalarial 
activity against P. falciparum in vitro and rodent malaria, P. berghei in vivo in 
mice (56, 57). Azithromycin, a structurally similar derivative of erythromycin is a 
macrolide antibiotic with a superior toxicological profile, and offers a number of 
advantages, including its safety in both children and pregnant women (58). The 
drug has demonstrated its efficacy for the treatment of uncomplicated falciparum 
malaria when used in combination with artesunate(59). In another in vitro 
combination study of azithromycin with artesunate demonstrated additive to 
synergistic interaction against clinical isolates (60). In the earlier study of 
azithromycin in combination with artesunate against culture-adapted parasite 
strains, however, Ohrt et al. suggested an additive to antagonistic interaction, 
explaining the limited success of this combination in early clinical trials(61, 62). 
While predicting clinical outcomes based on the results from in vitro study is 
largely limited and there remains a loose correlation between in vitro data and 
clinical outcomes, previous studies of azithromycin both in vitro and in vivo 
studies suggest that pharmacodynamics properties of azithromycin in combination 
with traditional antimalarial drugs should be further investigated. 





TABLE 1.2 Structural classification of antimalarial drugs used in study 




Pyronaridine  Aza-acridine mannich base 
Amodiaquine  4-aminoquinoline 
Tafenoquine  8-aminoquinoline 
Azithromycin  Macrolide antibiotics 
 





1.3 Rationale  
While there has been a dramatic progress in understanding P. falciparum genomics, and 
exciting discoveries of promising leads in the antimalarial pipeline, such as KAE609 and 
KAF156, both the safety and efficacy of these novel compounds remain to be assessed 
before testing in humans(63). Moreover, the efficacies of existing ACTs are threatened 
by incorrect dosing and non-compliance with duration of dosing regimen, which might 
hasten the emergence of resistant parasites. The increasing spread of P. falciparum 
isolates with a delayed clearance phenotype in the Mekong subregion of Southeast Asia 
has been a growing concern, and antimalarials in combinations, rather than as single 
drugs, are now recommended in order to prevent the emergence and spread of resistance 
(64-66). Understanding of the effects of drug interactions on combination therapy with 
existing antimalarial agents may provide useful information such as their mechanisms of 
action, and influence the development of new drug combinations in the future.  
 In the treatment of malaria, combinations of two or more drugs interact in either 
higher (synergism), or lower (antagonism) than would be expected from the individual 
activities simply added together while additive interactions simply indicate no 
interactions between drugs in combination. If antimalarial agents in combination is 
synergistic, it is favored as it suggests that the doses of each drug used may be reduced 
while maintaining its antimalarial effect and minimizing side effects. Conversely, 
combinations showing antagonistic interactions are generally avoided. Evaluation of drug 
interactions can be presented in an isobolograms, employing fractional inhibitory 
concentrations (FIC). The FIC is defined as the concentration of a drug present in the 





combination divided by the concentration of the drug alone that gives the same effect(67). 
In an additive combination, the sum of FICs of two drugs at the mid-point of a curve is 1, 
lying a straight line. With synergistic compounds, the sum of FICs is < 1, forming a 
concave line while  > 1 with convex line is seen in an antagonistic one. An advantage of 
employing FICs in an isobolograms, which dates back over 100 years, lies in its ability to 
show not only the difference between synergism or antagonism, but also the degree of 
interactions. In this type of illustration, median inhibitory concentration (IC50) (or any 
given effect such as killing or cure) values for one drug in the presence of various 
concentrations of another drug are plotted on the x-axis and vice versa on the y-axis. 
While a wide range of concentrations/ratios can be tested to generate isobolograms, 
interactions may dramatically differ at different ratios of two drugs, resulting in a skewed 
isobole. Two compounds in combination and their interactions are illustrated in Figure 
1.2 (68).  
 
Fig 1.3 Isobologram showing possible interactions between two compounds, A and B. Curve 1: additivity 
(no interaction); Curve 2: synergism; Curve 3: antagonism. A skewed isobole represented in dashed line. 
Reprinted by permission from Federation of European Microbiological Societies: Elsevier B.V. 
“Antimalarial drug synergism and antagonism: Mechanistic and clinical significance” by Angus Bell, 
copyright (2005).  





Traditionally, in vitro drug sensitivity assays have been commonly used to 
evaluate antimalarial drug efficacy and combined drug interactions in cultured cells at a 
very low parasitemia in a small volume of dilute blood by measuring the rate of 
suppression or inhibition of parasite growth during a 48-72 hour period. Such in vitro 
study captures a time dependent snapshot inhibition at different intervals of the 
intraerythrocytic P. falciparum, and measures antimalarial activity of drugs in question 
against the ring-stage parasites in comparison to untreated controls. In in vivo patient 
studies, however, cytocidal activity (or inhibition of parasite multiplication) is measured 
at a high asynchronous parasitemia (~ 1 trillion per adult). In severe falciparum malaria, 
the primary goal of antimalarial treatment is to save the life, and thus, therapeutic 
response in this case is determined by the speed of parasite killing, particularly the killing 
of ring-stage parasites in the circulation to prevent the progression to severe disease. Fast 
acting artemisinin and its derivatives such as artesunate show a superior effect on these 
young, developing-stage parasites over other antimalarial drugs(69-71). This argues in 
favor of an artemisinin-derivative in combination with slowly eliminated antimalarial 
drug in current guidelines of WHO-recommended antimalarials. Due to different 
measures (e.g., parasite lactate dehydrogenase (pLDH) enzyme, histidine-rich protein 2 
(HRP2), radio-labeled hypoxanthine) being assessed in in vitro drug suppression studies, 
however, results obtained from different assays may obscure their interpretations and 
become challenging to arrive at a sound conclusion(72-74). Moreover, the relationship 
between inhibition of parasite growth in vitro and parasite killing in vivo in respond to 
antimalarial drugs is not established, and it is unclear how well the standard in vitro 





susceptibility measures (e.g., 50% inhibitory concentrations [IC50], IC90) of static 
antimalarial drug activity correspond with drug interactions in humans. Extrapolating the 
results from cultured parasites to humans, therefore, requires in vivo studies in the 
relevant host. In recent years, rodent models have been developed to mimic human 
infections and predict therapeutic responses in the field(75). Examples of interactions 
between two antimalarial compounds both in animal and in vitro models are summarized 
in Table 1.3. The Plasmodium berghei model has been previously used to characterize 
pharmacokinetics and pharmacodynamics (PK/PD) profiles of antimalarials(76-78). In 
our study, we adapted a transgenic luciferase reporter, P. berghei ANKA to study 
cytocidal activity of antimalarials (i.e., tafenoquine, pyronaridine) in combination with 
artesunate, amodiaquine, and azithromycin at clinically relevant dosage. We initiated 
each drug treatment at a high parasitemia (~10%), and followed for 30 days. Three 
measures used in characterizing pharmacodynamics properties are 30-day survival, 
measure of parasite reduction over the first 24 to 48 hours, and recrudescent parasitemia 
(returned to initial parasitemia; 10
6 
parasites/µL). The parasite clearance time, which 
heavily depends on initial parasite biomass prior to drug treatment, is a measure that has 
been frequently used in previous studies. In the present study, we adapted the parasite 
reduction ratio (PRR) - the fractional reduction in total parasite numbers per asexual 
cycle – with pre-treatment parasitemia normalized to 10
6
 parasites/µL(79). The PRR or 
fractional log reduction in parasitemia is analogous to the killing rate, and the differences 
in PRR between antimalarial compounds reflect the different intrinsic pharmacodynamics 





between the drugs. In assessing interactions between two antimalarial compounds, 100% 
cure at day-30 was taken as a stringent measure to define synergy. 
 
TABLE 1.3 Drug interactions between antimalarial agents on Plasmodium spp.  
Plasmodium spp. Drug A Drug B Interaction Model Reference 
P. falciparum K1 PYR AZI Add. in vitro (80)  
P. falciparum K1, 3D7 TQ AS Ant. in vitro (81)  
P. falciparum K1,  PYR AS Ant. in vitro (82)  
P. falciparum 3D7 PYR AS Ant. in vitro (82) 
P. falciparum VS1 FCB PYR AS Ant. in vitro (82) 
P. falciparum TM9072a PYR AS Ant. in vitro (82) 
P. falciparum FCR3 PYR AS Ant. in vitro (82) 







Add. in vitro (84)  
P. falciparum C2A,B AZI Q Syn. in vitro (61)  
P. berghei ERT CQ Syn in vivo (85)  
PYR, pyronaridine; TQ, tafenoquine; AZI, azithromycin; ERT, erythromycin; AS, artesunate; ART, 
artemisinins; AMQ, amodiaquine; Q, quinine; CQ, chloroquine 
Ant, antagonism; Syn, synergism; Add, additivity. 
 
1.4 Research Aims  
We hypothesize that two quinoline-related compounds i.e., 8-aminoquinoline 
tafenoquine, and 4-aminoquinoline pyronaridine at various sub-curative doses synergize 
with three current antimalarial drugs, including artesunate, amodiaquine, and 
azithromycin, extending days return to initial parasitemia with greater log reduction in 
Plasmodium berghei parasites in vivo in mouse over a single parasitic life cycle (24 
hours), and making difference between cure and no cure. 
Aim 1. Determine the single, curative dose of pyronaridine or tafenoquine alone 
in vivo.  





Aim 2. Compare the pharmacodynamic interactions of tafenoquine versus 
pyronaridine in vivo.  
Aim 3. Characterize the interactions between tafenoquine or pyronaridine with 
artesunate in vivo. 
Aim 4. Evaluate the interactions between pyronaridine and another 4-























   
Antimalarial Drug Preparation and Dosing:  
Artesunate which constitutes 100% parent or acid, was dissolved in 5% sodium 
bicarbonate (NaHCO3). Stock solutions of the 4-aminoquinolines, amodiaquine and 
pyronaridine at 20 mg/mL and 5 mg/mL, respectively were prepared in deionized water 
and then diluted to the desired concentrations. The 8-aminoquinoline, tafenoquine at 5 
mg/mL was initially prepared in 1x phosphate-buffer saline (PBS 1x), sterile and then 
diluted with 12M HCl and 2M NaOH in 1:5 ratio in PBS 1x, sterile to the desired 
concentrations. Azithromycin was dissolved in 1M HCl, ethyl alcohol, 10 mM 
potassium-phosphate buffer (PPB) in 1:4:35 ratio. All drug stock solutions were prepared 
on the same day each dosing regimen was initiated and stored at -4
o
C until ready for use. 
Artesunate, pyronaridine, and azithromycin were administrated via intraperitoneal
                                                                                                              3. METHODOLOGY 
   24 
 injection in 200µL; amodiaquine and tafenoquine were administrated via oral gavage in 
200µL. The quinoline-related compounds – tafenoquine succinate (MW = 581.58, 80% 
free base), pyronaridine tetraphosphate (MW = 910.03, 56% free base), amodiaquine 
dihydrochloride (MW = 464.81, 76% free base) were dosed on salt weight. The 
conversion of the base/salt weight percentage is shown in the Table 2 alongside the 
human equivalent doses of each drug. All drugs were obtained from the Sigma-Aldrich.
In vivo Cytocidal Model of Murine Malaria:  
All experimentation was conducted under a protocol approved by the Animal Care and 
Use Committee of the Johns Hopkins University (MO16H91). Female BALB/c mice 
aged at least 6 weeks and weighing 20g   20% were used for all experimentation. Each 
mouse was infected via intraperitoneal injection with 500,000 erythrocytes infected with 
P. berghei ANKA-green florescent protein (GFP) – luciferase from a donor mouse. The 
original isolate was obtained from BEI Resources/American Type Culture Collection 
(ATCC) and transmitted through Anopheles stephensi mosquitoes to generate fresh stocks 
in 5 mice, from which blood was collected and aliquoted for frozen stocks. A donor 
mouse was prepared using a frozen stock, which was then passaged through no more than 
two mice before starting from a new fresh frozen stock for a new set of experiments. For 
all experiments, parasitemia in experimental mice was monitored by Giemsa-stained thin 
blood film in addition to luciferase analysis until approximately 10% parasitemia – 
equivalent to 10
6 
parasites/µL- was reached prior to initiating drug dosing regimens. Each 
drug treatment tested was replicated with three mice. 





Parasite Monitoring:  
Drug treatment was initiated at a high parasitemia (~10
6
 parasites/µL). Blood samples 
were collected at the time of the first drug dose, indicated as Time 0, 6h, 12h, and 24 h 
time-points post initial drug dose. Mice were followed up for 30 days with tail blood 
sampling to monitor daily parasitemia and survival, and euthanized when recrudescent 
parasitemia exceeded the initial parasitemia.  
 
Luciferase Assay Analysis: 
Our murine parasiticidal model utilizes a transgenic luciferase reporter, P. berghei-
ANKA to study cytocidal drug activity in vivo. The transgenic parasites expressing firefly 
luciferase enzyme, when combined with ATP-Mg
+2
 co-substrate, generate a flash of light, 
allowing us to detect and quantify parasite density in vivo at multiple end-points. 
Luciferase assay is comparable to blood films, and allows accurate analyses of 
intracellular infection mechanisms of the parasite and drug treatment outcomes. A few 
advantages of the assay include its ability to generate more time points than the standard 
method of Giemsa-stained blood films in a linear fashion over at least 4 orders of 
magnitude, demonstrating the reliability of this method to obtain data on relative parasite 
densities.  
 
Blood Sample Collection:  
Five microliters of blood samples from the tail of mice that had been infected with P. 
berghei-ANKA was collected and plated into 45µL of lysis buffer (20 mM Tris [pH 7.5], 





5 mM EDTA, 0.008% [wt./vol] saponin, and 0.08% [vol/vol] Triton X-100) in a 96-well 
plate. Blood samples were stored in - 80
o
 until processed for luciferase analysis(86). A 
total of 5µL of blood-lysis buffer (20 mM Tris, 5 mM EDTA, 0.008% saponin, 0.08% 
Triton x-100; pH=7.5) (whole-blood equivalent, 0.5µL) was transferred to a black, 
opaque 96-well plate, and 95µL of the luciferase buffer (200mM Tricine, 10mM EDTA, 
10mM K2CO3, 50mM MgSO4, 250µM dithiothreitol [DTT], 250µM ATP, 20µM D-
luciferin) was added. Samples were then processed for the luciferase assay, and luciferase 
activity was measured in the IVIS Spectrum in vivo imagining system and analyzed using 
Living Image v. 4.4 software.  
 
Data Analysis:  
The raw luciferase activity reported as radiant flux in photons per second was measured 
in the IVIS Spectrum in vivo imagining system and analyzed using Living Image v. 4.4 
software. The raw luciferase data log10 total flux (photons/second) were then 
transformed to parasites per microliter using the standard curve equation Y = (10^(log(y)-
0.55/0.05))*2 in GraphPad Prism 5 software(87). All data were normalized to 10
6 
parasites per microliter. Parasite reduction ratio was achieved by taking the difference of 
logarithmic exponents between initial parasitemia and that at 24-hour or 48-hour post 
dosing. Two-way analysis of variance (ANOVA) was performed to determine any 
statistically significant differences between comparing groups. For the evaluation of the 
effectiveness of drug combinations fractional inhibitory concentration (FIC) was 
employed using the 30-day survival profiles of various combinations tested.  





TABLE 2.1 Mouse doses and human equivalents of antimalarial drugs  
Antimalarial Drugs 
Mouse Dose 
Reference body weight: 0.02kg 
(Free base) 
Human Equivalent Dose: 
mouse dose x 0.081 
Reference body weight: 60kg 
(Free base) 
Artesunate 50 mg/kg (-) 4.1 mg/kg (-) 
Azithromycin 50 mg/kg (-) 4.1 mg/kg (-) 
Tafenoquine succinate 5 mg/kg (4) 0.41 mg/kg (0.33) 
10 mg/kg (8) 0.81 mg/kg (0.65) 
15 mg/kg (12) 1.2 mg/kg (0.96) 
20 mg/kg (16) 1.6 mg/kg (1.3) 
25 mg/kg (20) 2.0 mg/kg (1.6) 
30 mg/kg (24) 2.4 mg/kg (1.9) 
40 mg/kg (32) 3.2 mg/kg (2.6) 
Pyronaridine 
tetraphosphate 
2.5 mg/kg (1.4) 0.20 mg/kg (0.11) 
5 mg/kg (2.8) 0.41 mg/kg (0.23) 
7.5 mg/kg (4.2) 0.61 mg/kg (0.34) 
10 mg/kg (5.6) 0.81 mg/kg (0.45) 
40 mg/kg (22.4) 3.2 mg/kg (1.8) 
Amodiaquine 
dihydrochloride 
50 mg/kg (38) 4.1 mg/kg (3.1) 
100 mg/kg (76) 8.1 mg/kg (6.2) 
150 mg/kg (114) 12 mg/kg (9.1) 
200 mg/kg (152) 16 mg/kg (12) 
Reference: [USFDA 2005]. Human equivalent dose calculation factor obtained from FDA draft guidelines. 
FDA: Food and Drug Administration, HED: Human Equivalent Dose. Nair AB, Jacob S. A simple practice 























Results   
 
3.1 The minimum curative single oral administration of tafenoquine is 
30 mg/kg.  
The curative efficacy of a single dose of tafenoquine was evaluated in a cytocidal in vivo 
model with dose escalation at 10, 15, 20, 30, and 40 mg/kg. Tafenoquine succinate salt 
has free base at 80% of the total salt, and was administered to P. berghei-ANKA infected 
mice at a high initial parasitemia (~10%). Noncurative regimens included 10 mg/kg, and 
15 mg/kg with a return to initial parasitemia 5 days and 14 days post dosing, respectively.
The 20 mg/kg regimen was partially curative, resulted in 66% (n=2/3) recrudescence with 
return to initial parasitemia 14 days and 18 days post dosing (Fig 3.1.1A). 100% (n=3/3) 
cure was only achievable in the mice treated with either 30 mg/kg or 40 mg/kg (Fig 
3.1.1B). Parasite reduction ratio of each drug regimen for the single 24-hour life cycle, 





and the first 48 hours are expressed as the parasite log reduction in Table 3.1. Observed a 
log and 2-log-unit kill were seen within 48 hours for 30 and 40 mg/kg regimens, 
respectively with cure at day 30. It is interesting to note that an observed initial 
downward-sloping plateau phase followed by a log-linear fall was seen for 10, 20, 30 and 
40 mg/kg regimens in the single 24-hour life cycle, resulting in no statistically significant 
difference in the amount of parasite killing among the four regimens (data not shown). 
 
 
Fig 3.1.1 Determination of single minimum curative dose of tafenoquine (TQ) on P. berghei ANKA 
infection. Doses of 10, 15, and 20 (A) along with 30, and 40 mg/kg (B) of tafenoquine were administered at 
0h to female BALB/c mice. Time zero corresponds to a parasitemia of ~10% as determined by the 
percentage of infected erythrocytes in Giemsa stained blood films as well as luciferase assay. Parasitemia 
were monitored only by luciferase assay thereafter. The data are represented as means ± SEM, or individual 
mice when group survival varied, and were analyzed using two-way ANOVA. Each graph is annotated 














TABLE 3.1.1 Identifying the single minimum curative dose of tafenoquine, and resulting parasite 
log reduction on P. berghei ANKA infection
a
 






Proportion of mice with 
recrudescent parasitemia 
Day of return to 
initial parasitemia 
10 0.2 1 3/3 5,5,5 
15 1 2 3/3 14,14,14 
20 -0.2 1 2/3 14,17 
30 0.02 1 0/3 NA 
40 -0.2 2 0/3 NA 
a
Tafenoquine (10,15,20,30,40 mg/kg) was administered at 0h to female BALB/c mice. The starting 
parasitemia was ~10%, as determined by the percentage of infected erythrocytes in Giemsa-stained blood 
films and luciferase assay. NA is not applicable 
 
3.2 The minimum curative single intraperitoneal administration of 
pyronaridine is 10 mg/kg.  
In order to determine the minimum therapeutic dose of pyronaridine in vivo, we evaluated 
the cytocidal activities of three different regimens of 5, 10, and 40 mg/kg. Pyronaridine 
was administrated intraperitoneally in the form of pyronaridine tetraphosphate salt, 
containing 56% free base. Curative regimens included 10 and 40 mg/kg (Fig 3.2.1). The 5 
mg/kg regimen was partially curative, resulted in 66% (n=2/3) recrudescence with return 
to initial parasitemia 10, and 14 days post dosing. A 3-log-unit kill, followed by an 
additional log kill was observed over the single 24-hour life cycle for all dosing regimens 
(Table 3.2.1). 
 
TABLE 3.2.1 Identifying the single minimum curative dose of pyronaridine, and resulting 




Pyronaridine (5,10,40 mg/kg) was administered at 0h to female BALB/c mice. The starting parasitemia 
was ~10%, as determined by the percentage of infected erythrocytes in Giemsa-stained blood films and 
luciferase assay. NA is not applicable. 






Proportion of mice with 
recrudescent parasitemia 
Day of return to 
initial parasitemia 
5 3 4 2/3 10,14 
10 3 4 0/3 NA 
40 3 4 0/3 NA 






Fig 3.2.1 Determination of single minimum curative dose of pyronaridine (PYR) on P. berghei ANKA 
infection. Doses of 5,10 and 40 mg/kg of pyronaridine were administered at 0h to female BALB/c mice. 
Time zero corresponds to a parasitemia of ~10% as determined by the percentage of infected erythrocytes 
in Giemsa stained blood films as well as luciferase assay. Parasitemia were monitored only by luciferase 
assay thereafter. The data are represented as means ± SEM, or individual mice when group survival varied, 
and were analyzed using two-way ANOVA. Each graph is annotated with the initial parasitemia (Pi) and 
the luciferase assay limit of quantitation (LQ). **, p < 0.01. 
 
3.3 Pyronaridine exhibits more rapid killing than tafenoquine.  
To compare the pharmacodynamics effects of the 4-aminoquinoline pyronaridine to those 
of the 8-aminoquinoline tafenoquine, single dose of each drug was administered at 10 and 
40 mg/kg. Tafenoquine at 10 mg/kg was not curative, resulted in a return to initial 
parasitemia 5 days post dosing. In contrast, 100% (n=3/3) cure was achieved with10 
mg/kg pyronaridine with a 3-log-unit kill over 24-hour life cycle (Table 3.3.1). While the 
40 mg/kg regimen of both tafenoquine and pyronaridine were curative, pyronaridine 
achieved 1,000-fold  more reduction in the number of parasites over the single 24-hour 
parasitic life cycle, reaching the limit of quantification (~1,000 parasites/L) nearly 48 
hours faster than tafenoquine as illustrated in Figure 3.3.1.  












Proportion of mice with 
recrudescent parasitemia 
Day of return to 
initial parasitemia 
TQ 10 0.2 1 3/3 5,5,5 
PYR 10 3 4 0/3 NA 
     
TQ 40 -0.2 2 0/3 NA 
PYR 40 3 4 0/3 NA 
a 
TQ, tafenoquine; PYR, pyronaridine. NA not applicable.  
 
 
Fig 3.3.1 Curative efficacy of pyronaridine (PYR) versus tafenoquine (TQ) on P. berghei ANKA infection. 
Doses 10 and 40 mg/kg of pyronaridine or tafenoquine were administered at 0h to female BALB/c mice. 
Time zero corresponds to a parasitemia of ~10% as determined by the percentage of infected erythrocytes 
in Giemsa stained blood films as well as luciferase assay. Parasitemia were monitored only by luciferase 
assay thereafter. The data are represented as means ± SEM and were analyzed using two-way ANOVA. 
The graph is annotated with the initial parasitemia (Pi) and the luciferase assay limit of quantitation (LQ). 





3.4 Checkerboard experiments to examine in vivo drug interactions 
between tafenoquine or pyronaridine with ACT partner compounds.  
In order to further investigate the in vivo efficacy of tafenoquine or pyronaridine, we 
tested both curative and noncurative doses of tafenoquine (5,10,15,20, and 25 mg/kg) or 
pyronaridine (2.5,5, and 7.5 mg/kg) in combination with three current antimalarials, 
including artesunate, amodiaquine, and azithromycin. We then determined the impact of 
combination therapy versus each drug alone, juxtaposing the results with sets of 
published and unpublished data from the laboratory for comparison.  
 3.4.1 Tafenoquine synergizes with artesunate..  
Figure 3.4.1.1 illustrates the isobolograms obtained with tafenoquine (5,10,15,20, 
and 25 mg/kg) and 50 mg/kg-artesunate (1,2,4, or 6 days). Overall, a synergistic 
trend was observed between the two compounds. The parasite log reduction over 
24 to 48 hours of each combination was compared to those of tafenoquine or 
artesunate alone (Table 3.4.1.1). While there was no statistically significant 
difference observed in parasite reduction over the first 24 hours post dosing 
among tafenoquine (5 mg/kg)-artesunate (1,2,4-days) regimens, increasing the 
duration of artesunate responded with incremental 30-day survival, ultimately 
leading to 100% cure: 1-day (0%, n=0/3), 2-days (33%, n=1/3). 4-days (100%, 
n=3/3) (Fig 3.4.1.2A). When a noncurative, single dose of tafenoquine at 10 
mg/kg was administered with fast acting artesunate (2-days), a reduction of 
parasite numbers by a factor of approximately 100,000 was observed over the first 
24-hour life cycle (Fig 3.4.1.2B). This is 1,000-fold more killing in comparison to 





2-days duration of artesunate alone or a single day artesunate in combination with 
tafenoquine at 10 mg/kg over the first 24 hours. Overall, lower doses of 
tafenoquine in combination with a short duration of artesunate were not curative. 
The results of the combination therapy are summarized in Table 3.4.1.1  
 










Fig 3.4.1.1 Synergistic interaction between tafenoquine (TQ) and artesunate (AS) against P. berghei in 
mice. (A) Checkerboard showing single dose of tafenoquine on day 1 (vertical axis) and number of daily 
doses of 50 mg/kg of artesunate (horizontal axis), with average number of days to return to initial 
parasitemia indicated in each checkerboard box. C, 100% of mice (n=3/3) cured (no detectable parasitemia 
for 30 days); NT not tested; bolded C, data points used to construct isobolograms. Artesunate monotherapy 
results as previously reported (87). (B) Isobologram of cure at various tafenoquine dose ratios and 
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Fig 3.4.1.2 Determination of curative combination regimens of tafenoquine (TQ) with artesunate (AS) on 
P. berghei ANKA infection. Dose of 5 mg/kg of tafenoquine was administered at 0h to female BALB/c 
mice with artesunate (50mg/kg) for durations of 1, 2, or 4 days (A) along with 10 mg/kg of tafenoquine 
with 1 or 2 days of artesunate (B). Time zero corresponds to a parasitemia of ~10% as determined by the 
percentage of infected erythrocytes in Giemsa stained blood films as well as luciferase assay. Parasitemia 
were monitored only by luciferase assay thereafter. The data are represented as means ± SEM, or individual 
mice when group survival varied (A), and were analyzed using two-way ANOVA. Each graph is annotated 






























TABLE 3.4.1.1 Identifying curative combination regimens of tafenoquine with artesunate on P. 
berghei ANKA infection
a











Proportion of mice with 
recrudescent parasitemia 
Day of return to 
initial parasitemia 
1 b - 1 0.4 - - 
5 2 3 3/3 11,11,11 
10 2 2 3/3 5,4,4 
15 2 3 0/3 NA 
20 2 4 0/3 NA 
25 2 4 0/3 NA 
2 b - 2 3 - - 
5 2 5 2/3 12,12 
10 5 5 0/3 NA 
15 6 4 0/3 NA 
20 6 4 0/3 NA 
4 5 2 5 0/3 NA 
10 6 6 0/3 NA 
15 6 6 0/3 NA 
20 6 5 0/3 NA 
6 10 6 6 0/3 NA 
15 6 6 0/3 NA 
20 6 6 0/3 NA 
a
Single dose of tafenoquine (5,10,15,20,25 mg/kg) was administered at 0h in combination with artesunate 
(50 mg/kg) for durations of 1,2,4, or 6 consecutive days to female BALB/c mice. The starting parasitemia 
was ~10%, as determined by the percentage of infected erythrocytes in Giemsa-stained blood films and 
luciferase assay. NA is not applicable 
b




3.4.2 Pyronaridine exhibits additive interactions with artesunate. 
In vivo efficacy of pyronaridine was further explored in combination with 
artesunate in a curative model of P. berghei-ANKA infected mice. In combination 
with a low, noncurative dose of 2.5 mg/kg pyronaridine, extending the duration of 
artesunate from 1 day to 2 days prolonged recrudescence by a single day (Fig 
3.4.2.1A). In combination with a single day artesunate, increasing the dose of 
pyronaridine from 2.5 mg/kg to 5 mg/kg prolonged recrudescence to initial 
parasitemia from day 7 until day 11. While a single, noncurative dose of 
pyronaridine at 2.5 mg/kg and a single day artesunate alone share similar parasite 





log reduction profiles, the two compounds in combination demonstrated a 2-log-
unit kill over a single 24-hour parasitic life cycle, extending recrudescence to 
initial parasitemia by three days. Interestingly, all of combination regimens 
exhibited a 2-log-unit kill over the first 24 hours (Table 3.4.2.1). The greatest log 
reduction of the parasite biomass was achieved by 2.5 mg/kg of pyronaridine with 
artesunate (2 days) over the second parasitic life cycle (48 hours post dosing) with 
an additional 3-log-unit kill. 100% (n=3/3) cure was only achievable in the mice 
treated with 5 mg/kg and 7.5 mg/kg pyronaridine in combination with longer 
durations of artesunate treatment (2- and 4-days). While there was no statistically 
significant difference observed in parasite reduction over the first 24 hours post 
dosing among pyronaridine (2.5,5, or 7.5 mg/kg)-artesunate (2-days) regimens, 
increasing the dose of pyronaridine responded with prolonged recrudescence to 
initial parasitemia by 5 days and incremental 30-day survival, ultimately leading 
to 100% cure: 2.5mg/kg (0%, n=0/3), 5mg/kg (33%, n=1/3). 7.5mg/kg (100%, 
n=3/3) (Fig 3.4.2.1B). The overall interactions between the two antimalarial 
compounds were additive, and are illustrated in isobolograms in Figure 3.4.2.2.  






Fig 3.4.2.1 Determination of curative combination regimens of pyronaridine (PYR) with artesunate (AS) 
on P. berghei ANKA infection. Doses of 2.5, 5 and 7 mg/kg of pyronaridine were administered at 0h to 
female BALB/c mice with artesunate (50 mg/kg) for durations of 1, or 2 days. Time zero corresponds to a 
parasitemia of ~10% as determined by the percentage of infected erythrocytes in Giemsa stained blood 
films as well as luciferase assay. Parasitemia were monitored only by luciferase assay thereafter. The data 
are represented as means ± SEM, or individual mice when group survival varied (B), and were analyzed 
using two-way ANOVA. 1- and 2-day durations of artesunate monotherapy data obtained from separate 
experiments and juxtaposed for comparison. Each graph is annotated with the initial parasitemia (Pi) and 




TABLE 3.4.2.1 Identifying curative combination regimens of pyronaridine with artesunate on P. 
berghei ANKA infection
a











Proportion of mice with 
recrudescent parasitemia 




- 1 0.4 - - 
2.5 2 3 3/3 7,7,5 
5 2 4 3/3 12,14,12 
7.5 2 4 0/3 - 
2 b 
- 2 3 - - 
2.5 2 5 3/3 7,7,7 
5 2 5 2/3 12,12 
7.5 2 5 0/3 NA 
4 
2.5 2 5 3/3 9, 12, 13 
5 2 5 0/3 NA 
a
Single dose of pyronaridine (2.5,5, and 7.5 mg/kg) was administered at 0h in combination with artesunate 
(50 mg/kg) for durations of 1,2,or 4 consecutive days to female BALB/c mice. The starting parasitemia was 
~10%, as determined by the percentage of infected erythrocytes in Giemsa-stained blood films and 
luciferase assay. NA is not applicable 
b
Aretesunate monotherapy results as previously reported.  
 
 



















Fig 3.4.2.2 Additive interaction between pyronaridine and artesunate against P. berghei in mice. (A) 
Checkerboard showing single dose of pyronaridine on day 1 (vertical axis) and number of daily doses of 50 
mg/kg artesunate (horizontal axis), with average number of days to return to initial parasitemia indicated in 
each checkerboard box. C. 100% of mice (n=3/3) cured (no detectable parasitemia for 30 days after first 
dose); NT, not tested; bolded C, data points used to construct isobolograms. Artesunate monotherapy results 
as previously reported (87). (B) Isobologram of cure at various pyronaridine dose ratios and artesunate 




3.4.3 Pyronaridine synergizes with amodiaquine.  
Drug interactions of pyronaridine with another 4-aminoquinoline, amodiaquine 
were evaluated in vivo against P. berghei-ANKA. Four different doses of 
amodiaquine at 50,100,150, and 200 mg/kg were orally administrated in the form 
of amodiaquine dihydrochloride salt, containing 76% free base. An observed 3-
log-unit kill was seen over 24 hours in all treatment regimens (Fig 3.4.3.1 and 
Table 3.4.3.1). While 100% of the mice (n=3/3) cured the infection and survived 
until 30 days, when combination included 7.5 mg/kg of pyronaridine with 100 
mg/kg amodiaquine only a single mouse survived, resulting in 66%  (n=2/3) 
recrudescence, exceeding initial parasitemia levels by day 11, and 12 (data not 
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compounds in combination demonstrated 100-fold more reduction than 
amodiaquine alone over a single 24-hour life cycle. The isobolograms obtained 
with pyronaridine and amodiaquine are illustrated in Figure 3.4.3.2, and the 
results of the combination therapies are summarized in Table 3.4.3.1. Overall, 
synergistic effect was observed between the two compounds.  
 
Fig 3.4.3.1 Determination of curative combination regimens of pyronaridine (PYR) with amodiaquine 
(AMQ) on P. berghei ANKA infection. Dose of 2.5 mg/kg of pyronaridine was administered at 0h to 
female BALB/c mice with amodiaquine (100,150, or 200 mg/kg). Time zero corresponds to a parasitemia 
of ~10% as determined by the percentage of infected erythrocytes in Giemsa stained blood films as well as 
luciferase assay. Parasitemia were monitored only by luciferase assay thereafter. The data are represented 
as means ± SEM and were analyzed using two-way ANOVA. The graph is annotated with the initial 

















TABLE 3.4.3.1 Identifying a curative combination regimens of pyronaridine with amodiaquine 
on P. berghei ANKA infection
a











Proportion of mice with 
recrudescent parasitemia 
Day of return to 
initial parasitemia 
50 b - 1 3 - - 
5 3 6 0/3 NA 
 7,5 3 6 0/3 NA 
100 b - 1 3 - - 
2.5 3 6 0/3 NA 
5 3 6 0/3 NA 
 7.5 3 6 2/3 11.12 
150 b - 1 2 - - 
2.5 3 6 0/3 NA 
5 3 6 0/3 NA 
7.5 3 6 0/3 NA 
200 b - 1 2 - - 
2.5 3 6 0/3 NA 
5 3 6 0/3 NA 
 7.5 3 6 0/3 NA 
a
Single dose of pyronaridine (2.5,5,and 7.5 mg/kg) was administered at 0h in combination with 
amodiaquine (50,100,150, or 200 mg/kg) to female BALB/c mice. The starting parasitemia was ~10%, as 
determined by the percentage of infected erythrocytes in Giemsa-stained blood films and luciferase assay. 
NA is not applicable. 
b
Amodiaquine monotherapy results as previously reported.  
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Fig 3.4.3.2 Synergistic interaction between pyronaridine and amodiaquine against murine malaria, P. 
berghei in mice. (A) Checkerboard showing single dose of pyronaridine on day 1 (vertical axis) and single 
dose of amodiaquine (horizontal axis), with average number of days to return to initial parasitemia 
indicated in each checkerboard box. C, 100% of mice (n=3/3) cured (no detectable parasitemia for 30 days 
after first dose); NT; not texted, bolded C; data points used to construct isobolograms. Amodiaquine 
monotherapy results as previously reported. (B) Isobologram of cure at various pyronaridine dose ratios 
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3.4.4 Pyronaridine exhibits differential interactions with azithromycin.  
Using the same P. berghei-ANKA model, cytocidal activities of pyronaridine in 
combination with azithromycin were examined. Azithromycin at 50 mg/kg was 
intraperitoneally administered for 1,2,3,4,5, or 6 days along with a single dose of 
pyronaridine at 2.5,5, or 7.5 mg/kg. In combination with a low, noncurative dose 
of 2.5 mg/kg pyronaridine, extending the duration of azithromycin from 3 days to 
4 days did not result in a statistically significant difference in clearing the parasite 
biomass over the first 24 or 48 hours, and both regimens achieved 100% survival 
(n=3/3) at day 30 (Fig 3.4.4.1). Similarly, in combination with 3- or 5-days 
durations of azithromycin treatment, there was no evidence of enhanced cytocidal 
effect seen by increasing the dose of pyronaridine from 5 to 7.5 mg/kg, resulting 
in 3-log-unit kill over the single 24-hour parasitic life cycle followed by an 
additional log kill over the next cycle (data not shown). This was also evident 
from the maximal duration of azithromycin (6 days) with pyronaridine (5 mg/kg) 
with no additional killing achieved (data not shown). Overall, it was concluded 
that interactions are varying dependent on durations of azithromycin treatment; at 
least 3-days or longer durations of azithromycin must be co-administered with 
pyronaridine in order to achieve 100% cure in mice, and the two compounds 
exhibited both synergy and additive interactions at varying drug ratios (Fig 
3.4.4.2). The results of the combination therapies are summarized in Table 
3.4.4.1. 
 






Fig 3.4.4.1 Determination of curative combination regimens of pyronaridine (PYR) with azithromycin 
(AZI) on P. berghei ANKA infection. Dose of 2.5 mg/kg of pyronaridine was administered at 0h to female 
BALB/c mice with azithromycin (50 mg/kg) for durations of 3 or 4 days. Time zero corresponds to a 
parasitemia of ~10% as determined by the percentage of infected erythrocytes in Giemsa stained blood 
films as well as luciferase assay. Parasitemia were monitored only by luciferase assay thereafter. The data 
are represented as means ± SEM and were analyzed using two-way ANOVA. Pyronaridine (2.5 mg/kg) and 
3- and 4-days durations of azithromycin monotherapy data obtained from separate experiments and 
juxtaposed for comparison. The graph is annotated with the initial parasitemia (Pi) and the luciferase assay 





























TABLE 3.4.4.1 Identifying curative combination regimens of pyronaridine with azithromycin on 
P. berghei ANKA infection
a











Proportion of mice with 
recrudescent parasitemia 
Day of return to 
initial parasitemia 
1 2.5 -4 -5 3/3 7,8,7 
 5 1 1 3/3 12,1,12 
7.5 2 1 3/3 11,11,11 
2b - 0.3 0.5 - - 
2.5 -4 -5 3/3 14,14,5 
5 1 0.1 3/3 14,16,16 
7.5 1 1 3/3 14,14,14 
3b - 0.2 0.5 - - 
2.5 2 3 0/3 NA 
5 3 4 0/3 NA 
7.5 3 4 0/3 NA 
4b - 0.2 0.3 - - 
2.5 2 3 0/3 NA 
5 3 3 0/3 NA 
7.5 3 5 0/3 NA 
5b 
 
- 0.3 0.3 - - 
5 3 4 0/3 NA 
7.5 3 4 0/3 NA 
6 5 3 4 0/3 NA 
a
Single dose of pyronaridine (2.5,5,and 7.5 mg/kg) was administered at 0h in combination with 
azithromycin (50 mg/kg) for durations of 1,2,3,4,5,or 6consecutive days to female BALB/c mice. The 
starting parasitemia was ~10%, as determined by the percentage of infected erythrocytes in Giemsa-stained 
blood films and luciferase assay. NA is not applicable. 
b








































Fig 3.4.4.2 Differential interaction between pyronaridine and azithromycin against P. berghei in mice. 
(A) Checkerboard showing single dose of pyronaridine on day 1 (vertical axis) and number of doses of 50 
mg/kg azithromycin (horizontal axis), with average number of days to return to initial parasitemia indicated 
in each checkerboard box. C, 100% of mice (n=3/3) cured (no detectable parasitemia for 30 days after first 
dose); NT; not tested; bolded C; data points used to construct isobolograms. Azithromycin monotherapy 
results as previously reported. (B) Isobologram of cure at various pyronaridine dose ratios and 
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International guidelines have recommended the use of ACTs as a first-line treatment on a 
three-day course schedule for the treatment of uncomplicated falciparum malaria. Fast 
acting artemisinin derivatives with a short half-life such as artesunate can reduce the 
parasitic load by at least 10,000-fold within 48 hours of the parasitic life cycle, resulting 
in more than 95% clearance of initial infection. Artemisinin-based combination therapy 
remains important in many parts of malaria endemic countries, however, delay in parasite 
clearance has been detected as evident in decreased in vivo efficacy of 
dihydroartemisinin-piperaquine against P. falciparum infection in Southeast Asia(88). 
This necessitates discovery of novel antimalarials as well as search for better dosing 
regimens for the existing drugs. Our study aimed to address the latter by focusing on the 
cytocidal activities of two quinoline-related compounds, 4-aminoquinolines pyronaridine





and 8-aminoquinoline tafenoquine in a mouse model of malaria with a 24-hour parasitic 
asexual life cycle. We evaluated efficacies of pyronaridine and tafenoquine alone and in 
combination with three established antimalarial drugs, including artesunate, amodiaquine, 
and azithromycin. We hypothesized that both tafenoquine and pyronaridine would 
achieve greater reduction in the P. berghei biomass when administered with another 
antimalarials than monotherapy at their sub-curative doses.  
We adapted the luciferase reporter P. berghei for use in comparing the differential 
cytocidal activities of tafenoquine versus pyronaridine at the same dose of 10 and 40 
mg/kg. Considering the active base of tafenoquine succinate (80%), and pyronaridine 
tetraphosphate (76%), pyronaridine showed more potent cytocidal activity against P. 
berghei at the same total dose. This was evident from its rapid reduction of parasite 
density with 10,000-fold reduction over the first 48 hours post dosing, and cure at day 30 
at both 10 and 40 mg/kg. The observed reduction in parasite density were in agreement 
with previous in vivo experimental data(12). Tafenoquine at its curative doses (30, 40 
mg/kg), on the other hand, showed a strikingly different pattern of killing with a brief 
plateau followed by a log-linear fall. The plateau phase resembles the documented 
pharmacodynamics profile of quinine(89). As described in previous studies of 
chloroquine, for example, rapid parasite clearance presumably reflects a broader stage-
specificity of action, while initial plateau phase followed by a sustained fall as seen in 
tafenoquine indicates the killing of sequestered parasites rather than circulating ring 
stages(90, 91).  In the study of morphology of falciparum parasites following 
pyronaridine treatment, Kawai et al. has demonstrated that the earliest and most distinct 





effect of pyronaridine was on the parasite food vacuole of late trophozoites and 
schizonts(92). Similarly, falciparum parasites exhibit stage-specific drug response against 
commonly used antimalarials, quinine, 4-aminoquinoline chloroquine and artemisinin 
with the trophozoite and schizont stages considerably more sensitive to the drugs than the 
young ring stages(93).  
In addition to tafenoquine monotherapy, we determined the cytocidal effect of 
tafenoquine at its sub-curative doses in combination with artesunate. With five different 
doses of tafenoquine at 5, 10, 15, 20, 25 mg/kg, we have demonstrated that the lowest 
noncurative dose of 5 mg/kg tafenoquine achieves 100% cure with increased duration of 
artesunate: 1-day (0%), 2-day (33%), 4-days (100%). From available data, it is apparent 
that artemisinin derivatives must be present at least three parasitic life cycles (i.e., > 3 
days in P. berghei) to remove all of the parasites from the blood(12). While this seemed 
to hold true with the lower dose of tafenoquine (5 mg/kg), as we increased the dose of 
tafenoquine 2-day duration of artesunate was shown efficacious with 1,000-fold more 
killing with tafenoquine in comparison to artesunate alone. The observed plateau phase 
was not reproduced in the combination therapy. An early clinical study of combination 
treatment of 8-aminoquinoline primaquine with artesunate against asexual stage 
falciparum parasites has shown no evidence of synergy between the two compounds(94). 
While sharing a similar structure with primaquine, tafenoquine comes with a number of 
advantages over primaquine, including longer half-life, better schizontocidal action, and 
thus, the possibility of a shorter course of treatment. Our findings suggest that 
noncurative dosing regimens of tafenoquine gains the therapeutic potential when 





combined with fast acting artesunate as evident from a marked enhanced cytocidal 
activity against P. berghei and 30-day survival with tafenoquine at 15, 20, or 25 mg/kg 
with artesunate (1, 2, 4 days). As observed in the present study, tafenoquine seems to 
further reduce the residual parasites, preventing recrudescence, following the rapid killing 
and elimination of artesunate over the single life cycle. Similarly, the pyronaridine-
amodiaquine combination showed synergistic, resulting in 100% cure across most 
regimens. An observed 6-log-unit kill was seen in all combinations tested (3-log-unit kill 
in the single 24-hour life cycle), indicating no evidence of dose-response or concentration 
effect. This may suggest that with only one exposure at as low as 2.5 mg/kg of 
pyronaridine with 100 mg/kg of amodiaquine is sufficient for a maximal antimalarial 
effect, and the biological effects of pyronaridine-amodiaquine combination extend 
beyond their sub-curative concentrations in plasma.  
Pyronaridine-artesunate (Pyramax) is a newly introduced ACT at fixed-dose (3:1), 
and the only ACT registered for the treatment of both P. falciparum and P. vivax malaria. 
In the present study, we observed additive effects between with 2-log-unit kill over a 
single 24-hour life cycle across all regimens tested, resulting in approximately 10-fold 
more killing compared to artesunate (2 days) alone. Despite of enhanced cytocidal 
activity over the first 24 hours post dosing and superiority over monotherapy, our 
findings indicate that the effect was not sufficient to obtain a curative effect unless a 
longer durations of artesunate is administered. This is in contrast to synergistic 
interactions demonstrated in previous animal studies (26,27). In contrast, the 
pyronaridine-azithromycin combination showed mild antagonistic effects. A strong 





antagonism, by definition, refers to the loss of schizontocidal effect when the drugs are 
used in combination, requiring higher concentrations of the drugs to produce the same 
effect as the drugs alone(68). In the present study, azithromycin of fewer than 3-day 
duration failed to achieve 100% cure, suggesting that more than a total dose of 150 mg/kg 
must be present to obtain a curative effect with pyronaridine. Furthermore, increasing the 
durations of azithromycin or doses of pyronaridine did not seem to achieve greater killing 
than pyronaridine alone at 5mg/kg, suggesting that pyronaridine-azithromycin 
combinations do not interact in strict dose-response fashion. Our finding, in part agrees 
with a previous in vitro observation of pyronaridine-azithromycin, in which additive 
effects were determined(95). In the treatment of uncomplicated falciparum malaria in 
another study, higher doses of 1,000 or 1,500 mg of azithromycin for 5 and 3 days, 
respectively, were required in combination with quinine in order to achieve the same 
effects as with quinine-doxycycline combination(96). In 2003, White et al. in another 
study of quinine-rifampicin in a clinical trial of uncomplicated malaria observed clear 
antagonism. The study indicates that recrudescence rates were five times higher for the 
combination despite of the observed shorter parasite clearance times for the combination 
than for quinine alone. White et al. suggest that this was attributed to the increased 
conversion of quinine to its less potent 3-hydroxy derivative in the presence of rifampicin 
in patients. However, a clinical trial of azithromycin and chloroquine proved ineffective 
as single agents against uncomplicated falciparum malaria, while effective with more 
than 97% cure rate when combined, re-stating the therapeutic potential of the 
combination(97). As an antimalarial, azithromycin is relatively slow-killing, thus, 





requires faster acting partner compounds such as artemisinin-derivatives or 4-
aminoquinolines that will rapidly reduce the initial parasite burden. In fact, most 
antibiotics share a common characteristic of the late onset of antimalarial activity, called 
a delayed phenotype, which justifies its requirement for high initial drug concentrations 
to achieve moderate killing after 48 hours post dosing(98). Although not evident in the 
present study, long-lasting killing activity of azithromycin even after the drug is 
administered for 48 hours only is well documented(98). In the case of azithromycin in 
combination with pyronaridine, therefore, increasing the dose of azithromycin may 
ensure that concentrations remain at inhibitory level and longer in the plasma, allowing a 
greater chance of eradicating all of the parasites.  
Synergistic effect is certainly favorable in combination study and the ideal drug 
partner of pyronaridine should exert at least additive schizontocidal action. However, 
synergy and additive effects are not essential for successful treatment as some 
nonsynergistic combinations can be beneficial for chemotherapy such as quinine or 
mefloquine in combination with tetracycline, which showed additive effects in in 
vitro(99). Taking the results presented in our study in context with literature reports, it is 
reasonable to conclude that observed additive to mild antagonism between pyronaridine 
and artesunate or azithromycin do not justify the rejection of the combinations, 
particularly where one of the compounds is rapidly eliminated.  
By adapting a luciferase reporter, P. berghei, to study the cytocidal activities of 
antimalarials over at least a 30-day period, we have demonstrated the therapeutic 
potential of 4-aminoquinoline pyronaridine, and 8-aminoquinoline tafenoquine in 





combination with current antimalarials. Our data suggest that pyronaridine and 
tafenoquine at noncurative doses can achieve greater parasite killing over a single 
parasitic life cycle and 30-day survival by combining with artesunate, amodiaquine, or 
azithromycin.  
The above experimental data obtained from the present study, although consistent 
with clinical observations in part, were tested in murine malarial models in which the 
parasites were relatively drug sensitive, thus, parasite log reductions were maintained and 
reflect true intrinsic antimalarial activities of each drug. However, evidence of resistance 
to pyronaridine and the spread of P. falciparum isolates with a delayed clearance 
phenotype have been observed in certain areas of endemicity, suggesting the need for 
further investigation against drug-resistant strains of P. falciparum to design clinically 
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